{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T18:24:41Z","timestamp":1791915881944,"version":"4.3.4"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40257-026-01011-8","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T17:43:40Z","timestamp":1773078220000},"page":"217-226","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Defining Moderate Disease and Progression in Hidradenitis Suppurativa: An Expert Framework to Unlock the Window of Opportunity for Prompt Treatment"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1378-1590","authenticated-orcid":false,"given":"Antonio","family":"Martorell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Ingram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Falk G.","family":"Bechara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina L.","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thrasyvoulos","family":"Tzellos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haley B.","family":"Naik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Kirby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsey R.","family":"van Straalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Frew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivette","family":"Alarcon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Jordan M.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"issue":"4","key":"1011_CR1","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/jdv.12966","volume":"29","author":"CC Zouboulis","year":"2015","unstructured":"Zouboulis CC, Desai N, Emtestam L, Hunger RE, Ioannides D, Juh\u00e1sz I, et al. European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa. J Eur Acad Dermatol Venereol. 2015;29(4):619\u201344. https:\/\/doi.org\/10.1111\/jdv.12966.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1011_CR2","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jaad.2014.04.001","volume":"71","author":"AM Schrader","year":"2014","unstructured":"Schrader AM, Deckers IE, van der Zee HH, Boer J, Prens EP. Hidradenitis suppurativa: a retrospective study of 846 Dutch patients to identify factors associated with disease severity. J Am Acad Dermatol. 2014;71(3):460\u20137. https:\/\/doi.org\/10.1016\/j.jaad.2014.04.001.","journal-title":"J Am Acad Dermatol"},{"issue":"10476","key":"1011_CR3","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/s0140-6736(24)02475-9","volume":"405","author":"R Sabat","year":"2025","unstructured":"Sabat R, Alavi A, Wolk K, Wortsman X, McGrath B, Garg A, et al. Hidradenitis suppurativa. Lancet. 2025;405(10476):420\u201338. https:\/\/doi.org\/10.1016\/s0140-6736(24)02475-9.","journal-title":"Lancet"},{"issue":"9","key":"1011_CR4","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1111\/j.1468-3083.2009.03356.x","volume":"23","author":"J Revuz","year":"2009","unstructured":"Revuz J. Hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2009;23(9):985\u201398. https:\/\/doi.org\/10.1111\/j.1468-3083.2009.03356.x.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1011_CR5","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1046\/j.1468-3083.2001.00303.x","volume":"15","author":"T Jansen","year":"2001","unstructured":"Jansen T, Altmeyer P, Plewig G. Acne inversa (alias hidradenitis suppurativa). J Eur Acad Dermatol Venereol. 2001;15(6):532\u201340. https:\/\/doi.org\/10.1046\/j.1468-3083.2001.00303.x.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"1011_CR6","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.jaad.2019.08.090","volume":"82","author":"SR Goldburg","year":"2020","unstructured":"Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2020;82(5):1045\u201358. https:\/\/doi.org\/10.1016\/j.jaad.2019.08.090.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1011_CR7","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/bjd\/ljad345","volume":"190","author":"JG Krueger","year":"2024","unstructured":"Krueger JG, Frew J, Jemec GBE, Kimball AB, Kirby B, Bechara FG, et al. Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape. Br J Dermatol. 2024;190(2):149\u201362. https:\/\/doi.org\/10.1093\/bjd\/ljad345.","journal-title":"Br J Dermatol"},{"issue":"10","key":"1011_CR8","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1093\/ced\/llae120","volume":"49","author":"SA Merchant","year":"2024","unstructured":"Merchant SA, Shah SFH. The impact of hidradenitis suppurativa on work productivity and performance: a systematic review and\u00a0meta-analysis. Clin Exp Dermatol. 2024;49(10):1156\u201363. https:\/\/doi.org\/10.1093\/ced\/llae120.","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"1011_CR9","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.jaad.2019.06.1301","volume":"82","author":"A Garg","year":"2020","unstructured":"Garg A, Neuren E, Cha D, Kirby JS, Ingram JR, Jemec GBE, et al. Evaluating patients\u2019 unmet needs in hidradenitis suppurativa: results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project. J Am Acad Dermatol. 2020;82(2):366\u201376. https:\/\/doi.org\/10.1016\/j.jaad.2019.06.1301.","journal-title":"J Am Acad Dermatol"},{"key":"1011_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000537920","volume":"23","author":"JA Zahid","year":"2024","unstructured":"Zahid JA, Henning MAS, Bouazzi D, Jemec GBE. Questionnaire-based global prevalence of hidradenitis suppurativa: a systematic review and meta-analysis. Dermatology. 2024;23:1\u201310. https:\/\/doi.org\/10.1159\/000537920.","journal-title":"Dermatology"},{"key":"1011_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fmedt.2024.1200400","volume":"6","author":"J Kirby","year":"2024","unstructured":"Kirby J, Kim K, Zivkovic M, Wang S, Garg V, Danavar A, et al. Uncovering the burden of hidradenitis suppurativa misdiagnosis and underdiagnosis: a machine learning approach. Front Med Technol. 2024;6:1200400. https:\/\/doi.org\/10.3389\/fmedt.2024.1200400.","journal-title":"Front Med Technol"},{"issue":"6","key":"1011_CR12","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1111\/bjd.14038","volume":"173","author":"DM Saunte","year":"2015","unstructured":"Saunte DM, Boer J, Stratigos A, Szepietowski JC, Hamzavi I, Kim KH, et al. Diagnostic delay in hidradenitis suppurativa is a global problem. Br J Dermatol. 2015;173(6):1546\u20139. https:\/\/doi.org\/10.1111\/bjd.14038.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1011_CR13","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1159\/000508787","volume":"236","author":"G Kokolakis","year":"2020","unstructured":"Kokolakis G, Wolk K, Schneider-Burrus S, Kalus S, Barbus S, Gomis-Kleindienst S, et al. Delayed diagnosis of hidradenitis suppurativa and its effect on patients and healthcare system. Dermatology. 2020;236(5):421\u201330. https:\/\/doi.org\/10.1159\/000508787.","journal-title":"Dermatology"},{"issue":"Suppl 2","key":"1011_CR14","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/s0001-7310(17)30007-8","volume":"107","author":"A Martorell","year":"2016","unstructured":"Martorell A, Caballero A, Gonz\u00e1lez Lama Y, Jim\u00e9nez-Gallo D, L\u00e1zaro Serrano M, Miranda J, et al. Management of patients with hidradenitis suppurativa. Actas Dermosifiliogr. 2016;107(Suppl 2):32\u201342. https:\/\/doi.org\/10.1016\/s0001-7310(17)30007-8.","journal-title":"Actas Dermosifiliogr"},{"issue":"1","key":"1011_CR15","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/bjd.18983","volume":"184","author":"AV Marzano","year":"2021","unstructured":"Marzano AV, Genovese G, Casazza G, Moltrasio C, Dapavo P, Micali G, et al. Evidence for a \u201cwindow of opportunity\u201d in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study. Br J Dermatol. 2021;184(1):133\u201340. https:\/\/doi.org\/10.1111\/bjd.18983.","journal-title":"Br J Dermatol"},{"issue":"10","key":"1011_CR16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/ced\/llad191","volume":"48","author":"N Kearney","year":"2023","unstructured":"Kearney N, O\u2019Donohoe S, Hughes R, Kirby B. Shorter time to initiation of biologic therapy in the setting of a hidradenitis suppurativa specialty clinic. Clin Exp Dermatol. 2023;48(10):19\u201351. https:\/\/doi.org\/10.1093\/ced\/llad191.","journal-title":"Clin Exp Dermatol"},{"key":"1011_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1403455","volume":"11","author":"P Mendes-Bastos","year":"2024","unstructured":"Mendes-Bastos P, Benhadou F, Venturini M, Molina-Levya A, Thomas N, Alarcon I, et al. Biologic drugs in hidradenitis suppurativa: what does the GP have to know? A narrative review. Front Med. 2024;11:1403455. https:\/\/doi.org\/10.3389\/fmed.2024.1403455.","journal-title":"Front Med"},{"issue":"1","key":"1011_CR18","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/immuno4010004","volume":"4","author":"R Chen","year":"2024","unstructured":"Chen R, Guo R, Petty AJ, Jaleel T. Immune dysregulation and current targeted biologics in hidradenitis suppurativa. Immuno. 2024;4(1):57\u201376. https:\/\/doi.org\/10.3390\/immuno4010004.","journal-title":"Immuno"},{"issue":"5","key":"1011_CR19","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/jdv.20472","volume":"39","author":"CC Zouboulis","year":"2025","unstructured":"Zouboulis CC, Bechara FG, Benhadou F, Bettoli V, Bukvi\u0107 Mokos Z, Del Marmol V, et al. European S2k guidelines for hidradenitis suppurativa\/acne inversa part 2: treatment. J Eur Acad Dermatol Venereol. 2025;39(5):899\u2013941. https:\/\/doi.org\/10.1111\/jdv.20472.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1011_CR20","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00403-025-04016-1","volume":"317","author":"AV Marzano","year":"2025","unstructured":"Marzano AV, Bartoletti M, Bettoli V, Bianchi L, Chiricozzi A, Clerici M, et al. Hidradenitis suppurativa, from basic science to surgery and a new era of tailored targeted therapy: an expert opinion paper. Arch Dermatol Res. 2025;317(1):511. https:\/\/doi.org\/10.1007\/s00403-025-04016-1.","journal-title":"Arch Dermatol Res"},{"issue":"4","key":"1011_CR21","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/bjd.21673","volume":"187","author":"HC Ring","year":"2022","unstructured":"Ring HC, Yao Y, Maul JT, Ingram JR, Frew JW, Thorsen J, et al. The road to biologics in patients with hidradenitis suppurativa: a nationwide drug utilization study. Br J Dermatol. 2022;187(4):523\u201330. https:\/\/doi.org\/10.1111\/bjd.21673.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1011_CR22","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.jaad.2020.07.108","volume":"84","author":"LAV Orenstein","year":"2021","unstructured":"Orenstein LAV, Wright S, Strunk A, Garg A. Low prescription of tumor necrosis alpha inhibitors in hidradenitis suppurativa: a cross-sectional analysis. J Am Acad Dermatol. 2021;84(5):1399\u2013401. https:\/\/doi.org\/10.1016\/j.jaad.2020.07.108.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1011_CR23","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1111\/bjd.21798","volume":"187","author":"B Midgette","year":"2022","unstructured":"Midgette B, Strunk A, Akilov O, Alavi A, Ardon C, Bechara FG, et al. Factors associated with treatment satisfaction in patients with hidradenitis suppurativa: results from the Global VOICE project. Br J Dermatol. 2022;187(6):927\u201335. https:\/\/doi.org\/10.1111\/bjd.21798.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1011_CR24","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s40257-023-00796-2","volume":"24","author":"A Garg","year":"2023","unstructured":"Garg A, Geissb\u00fchler Y, Houchen E, Choudhary N, Arora D, Vellanki V, et al. Disease burden and treatment patterns among US patients with hidradenitis suppurativa: a retrospective cohort study. Am J Clin Dermatol. 2023;24(6):977\u201390. https:\/\/doi.org\/10.1007\/s40257-023-00796-2.","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"1011_CR25","doi-asserted-by":"publisher","first-page":"259","DOI":"10.4103\/sjg.sjg_190_23","volume":"29","author":"L Zhang","year":"2023","unstructured":"Zhang L, Jin Z, Hao J. Efficacy of early biologic therapy versus late\/conventional therapy in children and adolescents with Crohn\u2019s disease: a systematic review and meta-analysis. Saudi J Gastroenterol. 2023;29(5):259\u201368. https:\/\/doi.org\/10.4103\/sjg.sjg_190_23.","journal-title":"Saudi J Gastroenterol"},{"issue":"4","key":"1011_CR26","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s10067-008-1064-0","volume":"28","author":"S Jamal","year":"2009","unstructured":"Jamal S, Patra K, Keystone EC. Adalimumab response in patients with early versus established rheumatoid arthritis: DE019 randomized controlled trial subanalysis. Clin Rheumatol. 2009;28(4):413\u20139. https:\/\/doi.org\/10.1007\/s10067-008-1064-0.","journal-title":"Clin Rheumatol"},{"key":"1011_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izaa031","author":"S Hamdeh","year":"2020","unstructured":"Hamdeh S, Aziz M, Altayar O, Olyaee M, Murad MH, Hanauer SB. Early vs late use of anti-TNFa therapy in adult patients with Crohn disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2020. https:\/\/doi.org\/10.1093\/ibd\/izaa031.","journal-title":"Inflamm Bowel Dis"},{"key":"1011_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0697-z","author":"I Contreras-Y\u00e1\u00f1ez","year":"2015","unstructured":"Contreras-Y\u00e1\u00f1ez I, Pascual-Ramos V. Window of opportunity to achieve major outcomes in early rheumatoid arthritis patients: how persistence with therapy matters. Arthritis Res Ther. 2015. https:\/\/doi.org\/10.1186\/s13075-015-0697-z.","journal-title":"Arthritis Res Ther"},{"key":"1011_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003455","author":"A Ciurea","year":"2023","unstructured":"Ciurea A, G\u00f6tschi A, Br\u00e4m R, B\u00fcrki K, Exer P, Andor M, et al. Early axial spondyloarthritis according to the ASAS consensus definition: characterisation of patients and effectiveness of a first TNF inhibitor in a large observational registry. RMD Open. 2023. https:\/\/doi.org\/10.1136\/rmdopen-2023-003455.","journal-title":"RMD Open"},{"issue":"1","key":"1011_CR30","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/art.21519","volume":"54","author":"FC Breedveld","year":"2006","unstructured":"Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54(1):26\u201337. https:\/\/doi.org\/10.1002\/art.21519.","journal-title":"Arthritis Rheum"},{"key":"1011_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/art.24106","author":"V Bejarano","year":"2008","unstructured":"Bejarano V, Quinn M, Conaghan PG, Reece R, Keenan AM, Walker D, et al. Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum. 2008. https:\/\/doi.org\/10.1002\/art.24106.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"1011_CR32","doi-asserted-by":"publisher","first-page":"e236","DOI":"10.1111\/aos.15254","volume":"101","author":"AM Abu El-Asrar","year":"2023","unstructured":"Abu El-Asrar AM, Al Rashed FA, AlBloushi AF, Tobaigy MF, Gikandi PW, Herbort CP Jr., et al. Therapeutic window of opportunity in the acute uveitic phase of Vogt-Koyanagi-Harada disease: prevention of late autoimmune complications by early intervention. Acta Ophthalmol. 2023;101(2):e236\u201345. https:\/\/doi.org\/10.1111\/aos.15254.","journal-title":"Acta Ophthalmol"},{"key":"1011_CR33","doi-asserted-by":"publisher","unstructured":"Mu\u00f1oz-Barba D, Mart\u00ednez-Guill\u00e9n L, de la Sierra Gir\u00f3n-Prieto M, Arias-Santiago S, S\u00e1nchez-D\u00edaz M. The impact of cutaneous lupus erythematosus on major life-changing decisions: a cross-sectional study. J Dermatol. 2026;53(1):117\u201325. https:\/\/doi.org\/10.1111\/1346-8138.70010.","DOI":"10.1111\/1346-8138.70010"},{"issue":"6s","key":"1011_CR34","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1016\/j.jaad.2024.09.007","volume":"91","author":"CB Dagenet","year":"2024","unstructured":"Dagenet CB, Lee KH, Fragoso NM, Shi VY. Approach to the patient with hidradenitis suppurativa: evaluating severity to guide therapy. J Am Acad Dermatol. 2024;91(6s):S22\u20136. https:\/\/doi.org\/10.1016\/j.jaad.2024.09.007.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1011_CR35","doi-asserted-by":"publisher","first-page":"T213","DOI":"10.1016\/j.ad.2023.11.012","volume":"115","author":"FJ Melgosa Ramos","year":"2024","unstructured":"Melgosa Ramos FJ, Garc\u00eda-Ruiz R, Mateu Puchades A, Martorell A. [Translated article] Can we improve prognosis in hidradenitis suppurativa? Identifying patients in the window of opportunity. Actas Dermosifiliogr. 2024;115(2):T213\u20134. https:\/\/doi.org\/10.1016\/j.ad.2023.11.012.","journal-title":"Actas Dermosifiliogr"},{"key":"1011_CR36","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.jdin.2024.03.002","volume":"15","author":"N Holgersen","year":"2024","unstructured":"Holgersen N, Nielsen VW, Rosen\u00f8 NAL, Thyssen JP, Egeberg A, Nielsen SH, et al. Biomarkers of systemic inflammation are associated with disease severity and metabolic syndrome in patients with hidradenitis suppurativa. JAAD Int. 2024;15:170\u20138. https:\/\/doi.org\/10.1016\/j.jdin.2024.03.002.","journal-title":"JAAD Int"},{"issue":"3","key":"1011_CR37","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1001\/jamadermatol.2021.4926","volume":"158","author":"S Der Sarkissian","year":"2022","unstructured":"Der Sarkissian S, Hessam S, Kirby JS, Lowes MA, Mintoff D, Naik HB, et al. Identification of biomarkers and critical evaluation of biomarker validation in hidradenitis suppurativa: a systematic review. JAMA Dermatol. 2022;158(3):300\u201313. https:\/\/doi.org\/10.1001\/jamadermatol.2021.4926.","journal-title":"JAMA Dermatol"},{"key":"1011_CR38","doi-asserted-by":"crossref","unstructured":"Chovatiya R, Forman S, Alavi A, van der Zee HH, Miyagawa T, Gooderham M, et al. Bimekizumab efficacy by disease duration in moderate to severe hidradenitis suppurativa: 2-year phase 3 results from BE HEARD EXT (61888). AAD Congress; March 7\u201311, 2025; Orlando, FL, USA.","DOI":"10.1016\/j.jaad.2025.05.542"},{"issue":"7","key":"1011_CR39","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1007\/s13555-024-01209-w","volume":"14","author":"S Haselgruber","year":"2024","unstructured":"Haselgruber S, Fern\u00e1ndez-Crehuet-Serrano P, Fern\u00e1ndez-Ballesteros MD, Padial-G\u00f3mez A, Hern\u00e1ndez-Rodr\u00edguez JC, Ortiz-\u00c1lvarez J, et al. Insights into the window of opportunity and outcome measures in patients with moderate to severe hidradenitis suppurativa treated with secukinumab: a real-world study. Dermatol Ther Heidelb. 2024;14(7):1875\u201390. https:\/\/doi.org\/10.1007\/s13555-024-01209-w.","journal-title":"Dermatol Ther Heidelb"},{"key":"1011_CR40","unstructured":"van der Zee HH, Zouboulis CC, Reguiai Z, Guillem P, Hamzavi IH, Goldberg S, et al. The impact of lesion type on clinical response with secukinumab in patients with moderate to severe hidradenitis suppurativa: a post hoc analysis of the pooled data from SUNSHINE and SUNRISE phase 3 trials (P0186). EADV Congress; September 25\u221228, 2024; Amsterdam, The Netherlands."},{"key":"1011_CR41","unstructured":"Kimball AB, Alavi A, Jemec GBE, Zouboulis CC, Wozniak MB, Uhlmann L, et al. Secukinumab in moderate to severe hidradenitis suppurativa: week 16 results of Hurley Stage II and III from the SUNSHINE and SUNRISE phase 3 randomised trials (S-0901). EHSF Congress; February 8\u201310, 2023; Florence, Italy."},{"issue":"7","key":"1011_CR42","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s13555-023-00954-8","volume":"13","author":"M Oliveira","year":"2023","unstructured":"Oliveira M, Rahawi K, Duan Y, Lane M, Amin AZ, Sayed CJ. Effect of biologics on the need for procedural interventions, systemic medications, and healthcare utilization in patients with hidradenitis suppurativa: real-world data from the UNITE Registry. Dermatol Ther Heidelb. 2023;13(7):1577\u201385. https:\/\/doi.org\/10.1007\/s13555-023-00954-8.","journal-title":"Dermatol Ther Heidelb"},{"issue":"10443","key":"1011_CR43","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1016\/s0140-6736(24)00101-6","volume":"403","author":"AB Kimball","year":"2024","unstructured":"Kimball AB, Jemec GBE, Sayed CJ, Kirby JS, Prens E, Ingram JR, et al. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials. Lancet. 2024;403(10443):2504\u201319. https:\/\/doi.org\/10.1016\/s0140-6736(24)00101-6.","journal-title":"Lancet"},{"issue":"10378","key":"1011_CR44","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/s0140-6736(23)00022-3","volume":"401","author":"AB Kimball","year":"2023","unstructured":"Kimball AB, Jemec GBE, Alavi A, Reguiai Z, Gottlieb AB, Bechara FG, et al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet. 2023;401(10378):747\u201361. https:\/\/doi.org\/10.1016\/s0140-6736(23)00022-3.","journal-title":"Lancet"},{"issue":"3","key":"1011_CR45","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/ijd.17517","volume":"64","author":"S Haselgruber","year":"2025","unstructured":"Haselgruber S, Mu\u00f1oz-Barba D, Leon-P\u00e9rez FJ, Cuenca-Barrales C, Arias-Santiago S, Molina-Leyva A. Therapeutic burden in hidradenitis suppurativa: a cross-sectional study of 557 patients. Int J Dermatol. 2025;64(3):539\u201345. https:\/\/doi.org\/10.1111\/ijd.17517.","journal-title":"Int J Dermatol"},{"issue":"5","key":"1011_CR46","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1111\/bjd.15748","volume":"177","author":"CC Zouboulis","year":"2017","unstructured":"Zouboulis CC, Tzellos T, Kyrgidis A, Jemec GBE, Bechara FG, Giamarellos-Bourboulis EJ, et al. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity. Br J Dermatol. 2017;177(5):1401\u20139. https:\/\/doi.org\/10.1111\/bjd.15748.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1011_CR47","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/jdv.18632","volume":"37","author":"T Tzellos","year":"2023","unstructured":"Tzellos T, van Straalen KR, Kyrgidis A, Alavi A, Goldfarb N, Gulliver W, et al. Development and validation of IHS4-55, an IHS4 dichotomous outcome to assess treatment effect for hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2023;37(2):395\u2013401. https:\/\/doi.org\/10.1111\/jdv.18632.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1011_CR48","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20550","author":"JR Ingram","year":"2025","unstructured":"Ingram JR, Marzano AV, Prens E, Schneider-Burrus S, Warren RB, Keal A, et al. Hidradenitis suppurativa with and without draining tunnels: a real-world study characterizing differences in treatment and disease burden. J Eur Acad Dermatol Venereol. 2025. https:\/\/doi.org\/10.1111\/jdv.20550.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1011_CR49","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1159\/000529848","volume":"239","author":"PK Krajewski","year":"2023","unstructured":"Krajewski PK, Szepietowski JC, Martorell A. Tunnels in hidradenitis suppurativa: active inflammatory entities with specific molecular and genetic profiles\u2014a narrative review. Dermatology. 2023;239(3):323\u20137. https:\/\/doi.org\/10.1159\/000529848.","journal-title":"Dermatology"},{"issue":"10","key":"1011_CR50","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1097\/dss.0000000000001916","volume":"45","author":"A Martorell","year":"2019","unstructured":"Martorell A, Giovanardi G, Gomez-Palencia P, Sanz-Motilva V. Defining fistular patterns in hidradenitis suppurativa: impact on the management. Dermatol Surg. 2019;45(10):1237\u201344. https:\/\/doi.org\/10.1097\/dss.0000000000001916.","journal-title":"Dermatol Surg"},{"issue":"6","key":"1011_CR51","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1016\/j.jaci.2020.12.651","volume":"147","author":"K Navrazhina","year":"2021","unstructured":"Navrazhina K, Frew JW, Gilleaudeau P, Sullivan-Whalen M, Garcet S, Krueger JG. Epithelialized tunnels are a source of inflammation in hidradenitis suppurativa. J Allergy Clin Immunol. 2021;147(6):2213\u201324. https:\/\/doi.org\/10.1016\/j.jaci.2020.12.651.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"1011_CR52","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1111\/jdv.16183","volume":"34","author":"A Martorell","year":"2020","unstructured":"Martorell A, Jfri A, Koster SBL, Gomez-Palencia P, Solera M, Alfaro-Rubio A, et al. Defining hidradenitis suppurativa phenotypes based on the elementary lesion pattern: results of a prospective study. J Eur Acad Dermatol Venereol. 2020;34(6):1309\u201318. https:\/\/doi.org\/10.1111\/jdv.16183.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1011_CR53","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/bjd\/ljaf067","volume":"193","author":"JS Kirby","year":"2025","unstructured":"Kirby JS, Thorlacius L, Lambert J, Ciaravino V, Rolleri R, Pansar I, et al. Psychometric validation and interpretation thresholds of the Hidradenitis Suppurativa Quality of Life (HiSQOL\u00a9) questionnaire using pooled data from the phase III BE HEARD I & II trials of bimekizumab in hidradenitis suppurativa. Br J Dermatol. 2025;193(1):93\u2013104. https:\/\/doi.org\/10.1093\/bjd\/ljaf067.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1011_CR54","doi-asserted-by":"publisher","first-page":"412","DOI":"10.2340\/00015555-2513","volume":"97","author":"B Horv\u00e1th","year":"2017","unstructured":"Horv\u00e1th B, Janse IC, Blok JL, Driessen RJ, Boer J, Mekkes JR, et al. Hurley staging refined: a proposal by the Dutch Hidradenitis Suppurativa Expert group. Acta Derm Venereol. 2017;97(3):412\u20133. https:\/\/doi.org\/10.2340\/00015555-2513.","journal-title":"Acta Derm Venereol"},{"issue":"6, Supplement","key":"1011_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.06.348","volume":"83","author":"AB Kimball","year":"2020","unstructured":"Kimball AB, Sayed C, Duan Y, Longcore M, Crowley JJ. 16480 characteristics associated with progression of hidradenitis suppurativa: 2-year interim results from the HS UNITE registry. J Am Acad Dermatol. 2020;83(6, Supplement):AB65. https:\/\/doi.org\/10.1016\/j.jaad.2020.06.348.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"1011_CR56","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1001\/jamadermatol.2023.3282","volume":"159","author":"N Mastacouris","year":"2023","unstructured":"Mastacouris N, Tannenbaum R, Strunk A, Koptyev J, Aarts P, Alhusayen R, et al. Outcome measures for the evaluation of treatment response in hidradenitis suppurativa for clinical practice: a HiSTORIC consensus statement. JAMA Dermatol. 2023;159(11):1258\u201366. https:\/\/doi.org\/10.1001\/jamadermatol.2023.3282.","journal-title":"JAMA Dermatol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01011-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-026-01011-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01011-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T11:19:36Z","timestamp":1774696776000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-026-01011-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1011"],"URL":"https:\/\/doi.org\/10.1007\/s40257-026-01011-8","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"26 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Antonio Martorell\n                      has acted as a consultant, advisory board member, and investigator and received honoraria from Novartis, AbbVie, Janssen Cilag, UCB, Lilly, LEO Pharma, L'Oreal, Sanofi, Sandoz, Boehringer Ingelheim, MoonLake, Incyte, Legit.health, and Amgen.\n                      John R. Ingram\n                      has acted as a consultant and\/or advisory board member for AbbVie, Bluefin, Boehringer Ingelheim, Cantargia, ChemoCentryx, Citryll, Elasmogen, Engitix, Incyte, Indero, InflaRx, Insmed, Kymera Therapeutics, MoonLake, Novartis, Sun Pharma, UCB Pharma, UNION Therapeutics, and Viela Bio; he also received an editorial stipend from the\n                      British Journal of Dermatology\n                      as previous Editor-in-Chief and an author honorarium from UpToDate and is co-copyright holder of the Hidradenitis Suppurativa Quality of Life (HiSQoL) questionnaire and Investigator and Patient Global Assessment instruments for HS. JI\u2019s department receives royalties from the Dermatology Life Quality Index (DLQI) and related instruments.\n                      Christopher J. Sayed\n                      has acted as an investigator for AbbVie, AstraZeneca, ChemoCentryx, Incyte, InflaRx, Novartis, and UCB; has received consultancy fees from AbbVie, Alumis, AstraZeneca, InflaRx, Incyte, Logical Images, MoonLake Immunotherapeutics, Sandoz, Sanofi, Sonoma Biotherapeutics, and UCB; and has been a speaker for AbbVie, UCB, and Novartis.\n                      Falk G. Bechara\n                      has received honoraria for participation in advisory boards, in clinical trials, and\/or as a speaker for AbbVie Inc., AbbVie Deutschland GmbH & Co. KG, Acelyrin, Avalo, Boehringer Ingelheim Pharma GmbH & Co. KG, Celltrion, Incyte Corporation, Merck, M\u00f6lnlycke, MoonLake Immunotherapeutics, Novartis Pharma GmbH, Sitala, UCB, and Janssen-Cilag GmbH.\n                      Martina L. Porter\n                      has been a consultant and investigator for AbbVie, Avalo Therapeutics, Arcutis, Aristea Therapeutics, Eli Lilly and Company, Incyte, Janssen, Merck, MoonLake Immunotherapeutics, Navigator Biosciences, Novartis, Pfizer, Prometheus, Sanofi, Sonoma Biotherapeutics, UCB, and Zura Bio; a consultant for Almirall, FIDE, and Trifecta Clinical\/WCG; and an investigator for AnaptysBio, Bayer, Bristol Myers Squibb, OASIS Pharmaceuticals, Otsuka, Propeller Biosciences, and Regeneron; has received royalties from Beth Israel Deaconess Medical Center; and has received fellowship funding to institution from AbbVie.\n                      Thrasyvoulos Tzellos\n                      reports consultancy\/advisory boards\/speaker fees from AbbVie, Novartis, Boehringer Ingelheim, MSD, and UCB. He is the treasurer of the EHSF e.V.\n                      Haley B. Naik\n                      received consulting fees from AbbVie, Medscape, Sonoma Biotherapeutics, Union Chimique Belge (UCB), and Novartis; and holds shares in Radera, Inc. She is also an Associate Editor for\n                      JAMA Dermatology\n                      and Vice President of the Hidradenitis Suppurativa Foundation.\n                      Brian Kirby\n                      received research support from\/was a principal investigator (clinical trials) for AbbVie, Almirall, Janssen, Merck Sharpe Dohme, MoonLake Immunotherapeutics, Novartis, Pfizer, UCB, and Ventus; has been a consultant for AbbVie, Almirall, Astra Zeneca, Celgene, Janssen, Leo, MC2 Therapeutics, Merck Sharpe Dohme, MoonLake Immunotherapeutics, Novartis, Pfizer, UCB, and Union; has received honoraria from AbbVie, Almirall, Janssen, Lilly, MC2 therapeutics, MoonLake Immunotherapeutics, Novartis, Pfizer, UCB, and Union; and has been on scientific advisory boards for AbbVie, Almirall, GSK, Janssen, Lilly, MoonLake Immunotherapeutics, Novartis, Pfizer, and UCB.\n                      Kelsey R. van Straalen\n                      has received honoraria for participation in advisory boards, and\/or as a speaker for Boehringer Ingelheim, Novartis, and UCB.\n                      John W. Frew\n                      has conducted advisory work for Janssen, Boehringer Ingelheim, Pfizer, Kyowa Kirin, LEO Pharma, Regeneron, ChemoCentryx, AbbVie, Azora, Novartis, and UCB; participated in trials for Pfizer, UCB, Boehringer Ingelheim, Eli Lilly, CSL, and Azora; and received research support from Ortho Dermatologics, Sun Pharma, LEO Pharma, UCB, and La Roche Posay.\n                      Ivette Alarcon\n                      and\n                      Valeria Jordan M.\n                      are employees of Novartis and hold company stocks.\n                      Amit Garg\n                      is an advisor and receives honoraria from AbbVie, Almirall, Boehringer Ingelheim, Engitix, Immunitas Therapeutics, Incyte, Insmed, Novartis, Pfizer, Sonoma Biotherapeutics, Sun Pharma, UCB, Union Therapeutics, and Zura Bio, and receives honoraria.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All authors contributed to the conceptualization, visualization, drafting, reviewing, editing, and final approval of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Written informed consent for publication has been obtained from all individuals whose images are included in this manuscript, including informing them about the nature of the publication, the extent of the information to be published, and the potential for online publication and access by the general public.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}